详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.

129| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. [2]South Sichuan Institute of Translational Medicine, Luzhou, China. [3]Department of Pathophysiology, College of Basic Medical Science, Southwest Medical University, Luzhou, China. [4]Department of Oncology and Hematology, Hospital (T.C.M.) Affiliated to Southwest Medical University, Luzhou, China. [5]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Luzhou, China. [6]Department of Oncology Rehabilitation, Shenzhen Luohu People's Hospital, Shenzhen, China. [7]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, Hong Kong. [8]Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

出处：

DOI：

ISSN：

关键词： ImmTAC immunosuppression immunotherapy T-cell receptors suicide genes

摘要：

This review provides insight into the role of engineered T-cell receptors (TCRs) in immunotherapy. Novel approaches have been developed to boost anticancer immune system, including targeting new antigens, manufacturing new engineered or modified TCRs, and creating a safety switch for endo-suicide genes. In order to re-activate T cells against tumors, immune-mobilizing monoclonal TCRs against cancer (ImmTAC) have been developed as a novel class of manufactured molecules which are bispecific and recognize both cancer and T cells. The TCRs target special antigens such as NY-ESO-1, AHNAKS2580F or ERBB2H473Y to boost the efficacy of anticancer immunotherapy. The safety of genetically modified T cells is very important. Therefore, this review discusses pros and cons of different approaches, such as ImmTAC, Herpes simplex virus thymidine kinase (HSV-TK), and inducible caspase-9 in cancer immunotherapy. Clinical trials related to TCR-T cell therapy and monoclonal antibodies designed for overcoming immunosuppression, and recent advances made in understanding how TCRs are additionally examined. New approaches that can better detect antigens and drive an effective T cell response are discussed as well. Copyright © 2021 Zhao, Jiang, Xiang, Kaboli, Shen, Zhao, Wu, Du, Li, Cho, Li, Wen, Liu, Yi and Xiao.

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 2 区

医学

小类 | 2 区免疫学

最新[2023]版：

大类 | 2 区医学

小类 | 2 区免疫学

JCR分区：

出版当年[2021]版：

Q1 IMMUNOLOGY

最新[2023]版：

Q1 IMMUNOLOGY

影响因子： 5.7 最新[2023版] 6.8 最新五年平均 8.787 出版当年[2021版] 8.877 出版当年五年平均 7.561 出版前一年[2020版] 7.3 出版后一年[2022版]

第一作者：

第一作者机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. [2]South Sichuan Institute of Translational Medicine, Luzhou, China. [3]Department of Pathophysiology, College of Basic Medical Science, Southwest Medical University, Luzhou, China.

共同第一作者：

通讯作者：

通讯机构： [1]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China. [8]Department of Pharmacy, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons.

文献详情

相关文献